Dr. Robert Mach

Co-founder of Trevarx & Britton Chance Professor of Radiology and Director of the PET Radiochemistry Program, University of Pennsylvania

Trevarx-Upenn

ABSTRACT

Trevarx develops novel small molecule radiopharmaceutical platforms that provide a new oncology paradigm that identify and cure cancers. Its first radiopharmaceutical platform is a small molecule PARP inhibitor analogue with an α-emitting radiopharmaceutical therapeutic (α-RPT): (Astatine-211 Parthanatine or [211At]PTT) that delivers a cytotoxic radioactive payload directly to the PARP-1 residing on DNA. The antitumor effects of [211At]PTT have been demonstrated in-vivo in proof-of-concept studies in pediatric neuroblastoma and is currently in the pre-clinical phase with first in human trials to be performed in ovarian cancer in 2027 with expansion to prostate, breast cancer and pediatric neuroblastoma. [211At]PTT has a paired biomarker (Fluorine-18 Fluorthanatrace or [18F]FTT) that measures expression levels of PARP-1 in tumors that has been imaged in over 300 patients.

SPEAKER BIO

Dr. Mach is the Co-Founder of Trevarx and Inventor of [¹⁸F]FTT and [²¹¹At]PTT. He is the Britton Chance Professor of Radiology and Director of the PET Radiochemistry Program at the University of Pennsylvania. Dr. Mach is a past President of the Radiopharmaceutical Sciences Council of the Society of Nuclear Medicine & Molecular Imaging and a former member of the Board of Directors of the Society of Radiopharmaceutical Sciences. Research in his lab is focused on development of radiotracers for studying the molecular basis of disease using the imaging technique, positron emission tomography or PET. He holds 27 patents on the development of PET-based radiopharmaceuticals.

Return to conference agenda